An industry perspective on the Erice declaration and risk minimisation plans

Drug Safety

Volumn 29, Issue 8, 2006, Pages 733-734

  Ingate, Simon ^a   Tranter, Deborah ^a   Banerjee, Anjan ^a   Hobbs, Andrew ^a  

^a UK)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG INFORMATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HEALTH SURVEY; LETTER; MEDICAL PRACTICE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; UNITED STATES;

DRUG INDUSTRY; DRUG TOXICITY; GUIDELINES; GUIDELINES AS TOPIC; HUMANS; INTERDISCIPLINARY COMMUNICATION; RISK MANAGEMENT;

EID: 33746818230     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629080-00010     Document Type: Letter

References (5)

1. Hugman B. The erice declaration: the critical role of communication in drug safety. Drug Saf 2006; 29 (1): 91-3
2. Waller PC, Evans SJ, Beard K. Drug safety and the media. Br J Clin Pharmacol 2006; 61 (2): 123-6
3. Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2003; 12 (3): 183-94
4. Committee for Medicinal Products for Human Use (CHMP). Guideline on risk management systems for medicinal products for human use. European Agency for the Evaluation of Medicinal Products (EMEA). 2005 Nov
5. Food and Drug Centre for Drug Evaluation and Research (CDER). Guidance for industry, development and use of risk minimization action plans. 2005 Mar